BioStem Technologies, Inc. (BSEM)
0.8181
-0.12
(-12.50%)
USD |
NASDAQ |
Nov 18, 16:00
0.8181
0.00 (0.00%)
After-Hours: 20:00
BioStem Technologies Enterprise Value : 17.64M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 17.64M |
| November 16, 2026 | 18.11M |
| November 13, 2026 | 19.79M |
| November 12, 2026 | 24.45M |
| November 11, 2026 | 27.63M |
| November 10, 2026 | 19.60M |
| November 09, 2026 | 21.10M |
| November 06, 2026 | 21.28M |
| November 05, 2026 | 19.60M |
| November 04, 2026 | 21.66M |
| November 03, 2026 | 21.66M |
| November 02, 2026 | 21.84M |
| October 30, 2026 | 21.10M |
| October 29, 2026 | 24.27M |
| October 28, 2026 | 28.37M |
| October 27, 2026 | 27.81M |
| October 26, 2026 | 28.93M |
| October 23, 2026 | 29.49M |
| October 22, 2026 | 31.17M |
| October 21, 2026 | 31.55M |
| October 20, 2026 | 30.80M |
| October 19, 2026 | 28.93M |
| October 16, 2026 | 39.20M |
| October 15, 2026 | 38.26M |
| October 14, 2026 | 39.57M |
| Date | Value |
|---|---|
| October 13, 2026 | 42.18M |
| October 12, 2026 | 45.73M |
| October 09, 2026 | 46.29M |
| October 08, 2026 | 49.46M |
| October 07, 2026 | 44.80M |
| October 06, 2026 | 46.29M |
| October 05, 2026 | 51.61M |
| October 02, 2026 | 51.14M |
| October 01, 2026 | 57.49M |
| September 30, 2026 | 57.86M |
| September 29, 2026 | 62.52M |
| September 28, 2026 | 66.44M |
| September 25, 2026 | 68.04M |
| September 24, 2026 | 63.41M |
| September 23, 2026 | 61.98M |
| September 22, 2026 | 65.19M |
| September 21, 2026 | 72.68M |
| September 18, 2026 | 78.74M |
| September 17, 2026 | 71.96M |
| September 16, 2026 | 66.97M |
| September 15, 2026 | 65.73M |
| September 14, 2026 | 69.29M |
| September 11, 2026 | 71.07M |
| September 10, 2026 | 68.67M |
| September 09, 2026 | 69.29M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -54.16M |
| CorMedix, Inc. | 160.77M |
| Eloxx Pharmaceuticals, Inc. | -8.293M |
| Breakthrough Chemistry, Inc. | -0.0298M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.38M |
| Revenue (Quarterly) | 7.641M |
| Total Expenses (Quarterly) | 19.02M |
| EPS Diluted (Quarterly) | -0.6368 |
| Gross Profit Margin (Quarterly) | 46.95% |
| Profit Margin (Quarterly) | -148.9% |
| Earnings Yield | -287.0% |
| Normalized Earnings Yield | -286.99 |